



FOR IMMEDIATE RELEASE

CONTACT:
Kelly Sladek
SCORR Marketing
308.237.5567
Kelly@scormarketing.com

KCAS Strengthens Specialists Team

(Shawnee, Kansas; April 29, 2010) – [KCAS, LLC](#), a bioanalytical laboratory specializing in high-quality research and analytical services for pharmaceutical, biotech, animal health and medical device companies, is pleased to announce the addition of Masood Khan, Ph.D., to its growing team of experts. Dr. Khan will serve as senior director of ligand binding assay (LBA) services for KCAS.

For nearly 20 years, Dr. Khan has led wide-ranging research on the strategic planning for LBA programs, as well as the development of GLP-compliant and non-GLP assays for the conduct of ligand binding studies. He has chaired and organized countless academic conferences and round table lectures at annual forums and meetings of the American Association of Pharmaceutical Scientists' (AAPS) and has helped establish the LBAB-Focus Group, a specialty division of AAPS.

Dr. Khan has developed an impressive body of experience working in executive capacities for several major contract research organizations (CROs) and pharmaceutical companies including MDS Life Sciences, Covance, NeuroBiotech, MedImmune, Inc. and most recently the National Institute of Health. With over 100 publications and presentations to his credit, he continues to co-author authoritative reviews on the validation of LBA and biomarker assays. His recently edited book, *Ligand-Binding Assays: Development, Validation, and*

-more-

Implementation in the Drug Development Arena, is the most comprehensive reference book available in this area.

Dr. Khan received his Ph.D. in biochemistry from Aligarh University, India, and has conducted post-doctoral studies at the National Institute of Environmental Health Sciences in North Carolina and McGill University, Royal Victoria Hospital in Canada.

“His widespread expertise on ligand binding and years of experience in working with top CROs within the pharmaceutical industry will prove to be an asset for both him and us. We are very excited to welcome Dr. Khan onboard,” said President and Scientific Director of KCAS, Dari Dadgar, Ph.D.

With the capacity to analyze over 250,000 samples per year, KCAS provides clients with industry-leading bioanalytical services, including method development, validation and high-throughput sample analysis on biological samples for preclinical and clinical studies.

About KCAS, LLC

KCAS provides a full range of high-quality analytical services to pharmaceutical companies of all sizes. For more than 30 years, KCAS has provided bioanalytical services to pharmaceutical, biotech animal health and medical device companies. Delivering responsive, reliable and personalized results, KCAS boosts clients' bottom lines by enabling them to get drugs to market more quickly and effectively. For more information about KCAS, visit www.kcasbio.com.

###